Ropes & Gray Advises Akebia Therapeutics on Initial Public Offering
Ropes & Gray recently advised Akebia Therapeutics Inc. on its initial public offering of 6.7 million shares of its common stock at a price of $17 per share. Akebia is a Cambridge, Mass.-based biopharmaceutical company developing novel therapeutics aimed at patients with kidney disease. The IPO was announced Feb. 18 and closed March 25, with the net proceeds of the offering totaling $106.9 million.
Christopher Comeau led the Ropes & Gray team representing Akebia.